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Summary
Background The Papillomavirus Rapid Interface for Modelling and Economics (PRIME) has been used around the 
world to assess the health impact and cost-effectiveness of human papillomavirus (HPV) vaccination in girls. We 
updated PRIME with new data and methods for demography, disability weights, and cervical cancer burden, and 
generated revised estimates of the health impact of HPV vaccination at the global, regional, and national levels for 
177 countries.
Methods PRIME was updated with population demography of the UN World Population Prospects (UNWPP) 2019 
revision, disability weights of the Global Burden of Disease (GBD) 2017 study, and cervical cancer burden from the 
Global Cancer Incidence, Mortality and Prevalence (GLOBOCAN) 2018 database. We estimated the lifetime health 
benefits for bivalent or quadrivalent and nonavalent vaccination of 9-year-old and 12-year-old girls at 90% coverage 
during 2020–29 in 177 countries. Health impact was presented in terms of cervical cancer cases, deaths, or disability-
adjusted life-years (DALYs) averted per 1000 vaccinated girls in comparison with the counterfactual scenario of no 
vaccination, and the number of girls needed to be vaccinated to prevent a single case, death, or DALY.
Findings In estimating the health impact of HPV vaccination of 9-year-old girls, the combined updates to demography, 
disability weights, cervical cancer burden estimates resulted in a 26% increase in the estimated number of cases 
averted, a 51% increase in deaths averted, and a 72% increase in DALYs averted per 1000 vaccinated girls for both the 
bivalent or quadrivalent and nonavalent vaccines, compared with previous estimates. With the updated model, the 
bivalent or quadrivalent HPV vaccine was estimated to avert 15 cases, 12 deaths, and 243 DALYs per 1000 vaccinated 
girls, and the nonavalent HPV vaccine was estimated to avert 19 cases, 14 deaths, and 306 DALYs per 1000 vaccinated 
girls. The health benefits of vaccination of 12-year-old girls were estimated to be similar but slightly decreased in 
comparison with vaccination of 9-year-old girls.
Interpretation HPV vaccination provides greater health benefits and is more cost-effective than was previously 
estimated. The demography update, which incorporates population aging, has the largest effect on the health impact 
estimates. The WHO African region is expected to gain the greatest health benefits and should be prioritised for 
HPV vaccination.
Funding Gavi, the Vaccine Alliance; Bill & Melinda Gates Foundation.
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Cervical cancer has the fourth greatest global burden of 
cancer among women for both incidence and mortality, 
and is the leading cause of cancer death among women 
in 42 countries.1 WHO estimated that 570 000 new 
cases occurred and 311 000 women died from cervical 
cancer globally in 2018, with nearly 90% of these 
deaths occurring in low-income and middle-income 
countries.2,3
Cervical cancer is caused by infection with high-risk 
genotypes of human papillomavirus (HPV). Three HPV 
vaccines (bivalent, quadrivalent, and nonavalent) are 
widely available in the global market, and are highly 
efficacious in preventing persistent infection and 
associated disease from the high-risk HPV 16/18 geno -
types, which cause 70% of all cervical cancers.4–7 In 
addition to HPV 16/18, the nonavalent vaccine also 
protects against high-risk HPV types 31/33/45/52/58 
which cause 18·5% of HPV-positive cervical cancers.8
WHO recommends that all countries introduce HPV 
vaccination for primary prevention of cervical cancer, 
prioritising the primary target group of young adolescent 
girls, aged 9–14 years.9 Secondary prevention includes 
screening and treatment of precancerous lesions, and 
tertiary prevention includes diagnosis and treatment of 
invasive cervical cancer and palliative care.
In May, 2018, the WHO Director-General called for 
global action to eliminate cervical cancer as a public 
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health problem through improved coverage for HPV 
vaccination, high-precision screening tests, and 
treatment and care.10 The proposed 90–70–90 targets for 
2030 comprise 90% coverage of HPV vaccination among 
girls by 15 years of age; 70% coverage of screening among 
women at 35 and 45 years of age and 90% treatment of 
precancer lesions; and 90% coverage of treatment and 
care among women diagnosed with cervical cancer. 
Achieving this aim will require up-to-date estimates of 
the impact and cost-effectiveness of HPV vaccination at 
the global, regional, and national levels.
The Papillomavirus Rapid Interface for Modelling and 
Economics (PRIME) is a model to assess the health impact 
and cost-effectiveness of HPV vaccination of girls for 
prevention of cervical cancer.11,12 It was developed in 2014 in 
collaboration with WHO and has been validated against 
17 published studies set in low-income and middle-income 
countries. It is endorsed by the WHO Immunization and 
Vaccines Implementation Research Advisory Committee 
to provide a conservative estimate of the health impact and 
cost-effectiveness of vaccinating girls before sexual 
debut.11,13 PRIME has been used to inform the impact of 
vaccine investments by Gavi, the Vaccine Alliance, in 
97 countries, as well as at the national level.11,12,14
Since PRIME was developed, the nonavalent HPV 
vaccine was licensed in 2014, and new data and methods 
for demography, disability weights, and cervical cancer 
burden have become available. We have updated vaccine 
impact estimates generated by PRIME to reflect almost a 
decade of new data and assessed the effects of these updates 
on estimates at the global, regional, and national levels.
Methods
Data inputs and modelling process in PRIME
PRIME is a static proportional impact model that 
estimates the impact of both single-age and multiple-age 
cohort vaccination. Vaccination impact is estimated in 
terms of reduction in age-dependent cervical cancer 
incidence, prevalence, and mortality in direct proportion 
to vaccine coverage, vaccine efficacy, and distribution of 
high-risk HPV types (HPV 16/18 for the bivalent and 
quadrivalent vaccines and HPV 16/18/31/33/45/52/58 
for the nonavalent vaccine).5 Herd effects and cross-
protection are not considered; therefore, the estimated 
health benefits of HPV vaccination of 9–14-year-old girls 
are conservative. Vaccinating girls before sexual debut 
fully protects them from developing cervical cancer 
caused by high-risk HPV types, in accordance with the 
efficacy observed in vaccine trials.15 Waning of vaccine-
induced immunity against high-risk HPV types has 
not been empirically observed in follow-up studies 
since HPV vaccine introduction. The model assumes a 
two-dose schedule with perfect timeliness to the target 
ages given in the coverage estimates. Model equations 
and parameters have been extensively described 
elsewhere.11 Instructions for accessing the PRIME model 
and software are provided in appendix 1 (p 2).
PRIME data inputs include country and age-specific 
cervical cancer incidence, prevalence, and mortality 
among females from the Global Cancer Incidence, 
Mortality and Prevalence (GLOBOCAN) database.16 
We updated PRIME with new data and methods for 
demography, disability weights, and cervical cancer 
Research in context
Evidence before this study
The Papillomavirus Rapid Interface for Modelling and Economics 
(PRIME) was developed in 2014 in collaboration with WHO to 
assess the health impact and cost-effectiveness of human 
papillomavirus (HPV) vaccination in girls around the world. It was 
used to show that vaccinating 12-year-old girls against HPV was 
cost-effective in almost every country for the bivalent and 
quadrivalent vaccines. Since its development and the introduction 
of a nonavalent vaccine in 2014, new data and methods for 
demography from the UN World Population Prospects 2019 
revision, disability weights from the Global Burden of Disease 2017 
study, and cervical cancer burden from the Global Cancer 
Incidence, Mortality and Prevalence 2018 database have become 
available, and were used to update the model.
Added value of this study
The combined PRIME updates for demography, disability 
weights, and cervical cancer burden improve the HPV 
vaccination impact estimates in comparison with previous 
forecasts and suggest greater health benefits in preventing 
cases, deaths, and disability-adjusted life-years (DALYs) due to 
cervical cancer at the global, regional, and national levels. The 
demography update has the largest effect on the health impact 
estimates; population aging leads to increasing life expectancy 
among women and an increase in lifetime risk of cervical cancer 
incidence and mortality without vaccination. HPV vaccination 
can avert this potential increase in new cases and deaths, and 
because the number of girls needed to be vaccinated to prevent 
a single case, death, or DALY is lower than previous forecasts, 
HPV vaccination both provides greater health benefits and is 
more cost-effective than was previously estimated. Because of a 
higher burden of cervical cancer before vaccination in the WHO 
African region compared with other regions, HPV vaccination 
will provide the greatest health benefits in this region.
Implications of all the available evidence
Reaching the WHO goal of global elimination of cervical cancer 
as a public health problem will take decades. Therefore, HPV 
vaccine impact models, such as PRIME, need to regularly 
integrate new knowledge and updated data sources. With such 
updates, HPV vaccination remains highly cost-effective globally, 
and efforts to increase coverage and equity should be 
continued. Countries in the WHO African region should be 
prioritised for HPV vaccine introduction and scale-up.
For the PRIME tool see 
http://primetool.org
See Online for appendix 1
For the GLOBOCAN database 
see http://gco.iarc.fr
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burden and assessed the impact of these updates on 
health impact estimates generated by the model for the 
bivalent, quadrivalent, and nonavalent vaccines. All 
data were from secondary sources in the public domain, 
and therefore ethics approval was not required.
PRIME uses country-specific life tables to model 
the annual population size of longitudinal birth 
cohorts. The life tables were previously generated from 
population size of birth cohorts and all-cause female 
mortality estimates by age from the WHO 2009 Global 
Health Observatory, which remained static over time.17 
We updated the life tables to use population size and 
all-cause female mortality estimates from the UN World 
Population Prospects (UNWPP) 2019 revision, which 
varies dynamically over time during 1950–2100.18
Disability weights were updated from estimates of the 
Global Burden of Disease (GBD) 2001 study19 to 
estimates of the GBD 2017 study.20,21 Disability weights 
Figure 1: Lifetime cervical cancer burden before and after vaccination of 9-year-old girls at the global level
Lifetime cervical cancer burden is shown in terms of cases, deaths, and DALYs, before and after bivalent or quadrivalent and nonavalent HPV vaccination of 9-year-old girls 
at 90% coverage in 177 countries during 2020–29, which relates to birth cohorts of 2011–2020 (estimates after the combined PRIME updates for demography, disability 
weights, and cervical cancer burden). DALY=disability-adjusted life-year. HPV=human papillomavirus. PRIME=Papillomavirus Rapid Interface for Modelling and Economics.
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and GBD-prescribed durations for the different phases of 
cervical cancer (ie, diagnosis and primary treatment 
phase, controlled phase, metastatic phase, and terminal 
phase) in the GBD 2001 and GBD 2017 studies are 
presented in appendix 1 (pp 3, 4).22 In the GBD 2001 study, 
the morbidity impact of years lived with disability (YLD) 
was attributed to the specific year of incidence of new 
cases. In the GBD 2017 study, the morbidity impact was 
attributed to the specific years of prevalence of women 
experiencing the different phases of cervical cancer.
Cervical cancer burden was updated from the 
International Agency for Research on Cancer estimates 
for GLOBOCAN 201223 to GLOBOCAN 2018.1 The 
GLOBOCAN 2012 and 2018 databases provide country-
specific cancer burden data by 5-year age groups and sex 
for 28 types of cancer in 184 countries (GLOBOCAN 
2012) and 36 types of cancer in 185 countries 
(GLOBOCAN 2018).
HPV vaccine impact on cervical cancer burden 
(incidence, prevalence, and mortality) averted is 
calculated as the proportional reduction in age-specific 
incidence, prevalence, and mortality in each country at 
single-year age intervals from 0–100 years. Cervical 
cancer burden was calculated as follows: let v be the age 
at vaccination and i any given age, where v is less than or 
equal to i; then cervical cancer burden averted at age i is 
the product of five estimates: cervical cancer burden 
caused by all HPV genotypes at age i before vaccination, 
country-specific proportion of cervical cancer caused by 
high-risk HPV types, two-dose vaccine coverage at age v, 
vaccine efficacy against high-risk HPV types, and 
proportion of female population that has not experienced 
sexual debut by age v.
Comparative scenarios
We analysed five scenarios to assess the health impact of 
HPV vaccination using PRIME (appendix 1 p 5). The 
base scenario (S1) is based on demography from WHO 
2009 life tables, disability weights from the GBD 2001 
study, and cervical cancer burden estimates from the 
GLOBOCAN 2012 database. In comparison with S1, 
scenario 2 (S2) incorporates demography from UNWPP 
2019 revision, scenario 3 (S3) incorporates disability 
weights from the GBD 2017 study, and scenario 4 (S4) 
incorporates cervical cancer burden estimates from the 
GLOBOCAN 2018 database. Scenario 5 (S5) shows the 
combined effect of using all three of the updated demog-
raphy, disability weight, and cervical cancer burden 
estimates. We estimated the lifetime impact of routine 
vaccination of girls at 90% coverage (as recommended 
in the WHO cervical cancer elimination strategy) for 
the 10-year period of 2020–29 in comparison with the 
counterfactual scenario of no vaccination in 177 countries 
for bivalent or quadrivalent and nonavalent vaccination 
of 9-year-old and 12-year-old girls.
Vaccine impact metrics
We present vaccine impact metrics in terms of cervical 
cancer burden averted per 1000 vaccinated girls and 
number of girls needed to be vaccinated to prevent a single 
cervical cancer case, death, YLD, year of life lost (YLL), or 
disability-adjusted life-year (DALY). These two vaccine 
impact metrics are not affected by vaccination coverage, 
with the limitation that PRIME includes only direct effects 
of HPV vaccination and excludes indirect herd effects.
Role of the funding source
The funders of this study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the manuscript. All authors had full access to 
data in the study, and final responsibility for the decision 
to submit for publication.
Results
PRIME was updated with population demography from 
the UNWPP 2019 revision, disability weights from the 
GBD 2017 study, and cervical cancer burden from the 
GLOBOCAN 2018 database. Figure 1 presents the 
updated global estimates for lifetime burden of all 
cervical cancer before and after vaccination of 9-year-old 
girls with bivalent or quadrivalent and nonavalent 
vaccines at 90% coverage during 2020–29 in 177 countries. 
The equivalent estimates for 12-year-old girls are 
presented in appendix 1 (p 6). In addition, the estimates 
of lifetime burden of cervical cancer before and after 
vaccination at 90% coverage of 9-year-old and 12-year-old 
girls by HPV genotype (HPV 16/18 and HPV 
16/18/31/33/45/52/58) are presented at the global, 
regional, and national levels in the appendices (global, 
appendix 1 pp 7–14; regional, appendix 1 pp 15–135; 
national, appendix 1 p 136 and appendix 2). 
Table 1 presents the health impact of bivalent or 
quadrivalent and nonavalent HPV vaccination of 9-year-old 
girls at 90% coverage during 2020–29 on the lifetime 
Bivalent or quadrivalent HPV vaccination 
impact on cervical cancer caused by HPV 16/18
Nonavalent HPV vaccination impact on cervical 
cancer caused by HPV 16/18/31/33/45/52/58
Cases Deaths YLDs YLLs DALYs Cases Deaths YLDs YLLs DALYs
S1 12·2 7·6 9·6 131 141 15·4 9·6 12 166 178
S2 16·3 11·4 13·1 231 244 20·5 14·4 16·4 291 307
S3 12·2 7·6 4·4 131 136 15·4 9·6 5·5 166 171
S4 11·4 7·8 9 134 143 14·4 9·8 11·3 169 180
S5 15·4 11·5 7·9 235 243 19·3 14·4 9·9 296 306
Values are calculated on the basis of HPV vaccination of 9-year-old girls at 90% coverage during 2020–29, and they 
reflect the averted lifetime burden of cervical cancer in 177 countries for five comparative scenarios. All values are 
numbers averted per 1000 vaccinated girls. S1=Base scenario: WHO 2009 demography, GBD 2001 disability weights, 
GLOBOCAN 2012 cervical cancer burden. S2=Scenario 2: UNWPP 2019 demography, GBD 2001 disability weights, 
GLOBOCAN 2012 cervical cancer burden. S3=Scenario 3: WHO 2009 demography, GBD 2017 disability weights, 
GLOBOCAN 2012 cervical cancer burden. S4=Scenario 4: WHO 2009 demography, GBD 2001 disability weights, 
GLOBOCAN 2018 cervical cancer burden. S5=Scenario 5: UNWPP 2019 demography, GBD 2017 disability weights, 
GLOBOCAN 2018 cervical cancer burden. HPV=human papillomavirus. YLD=year lived with disability. YLL=year of life 
lost. DALY=disability-adjusted life-year. GBD=Global Burden of Disease study. GLOBOCAN=Global Cancer Incidence, 
Mortality and Prevalence. UNWPP=UN World Population Prospects.
Table 1: Global estimates of the impact of HPV vaccination of 9-year-old girls
See Online for appendix 2
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burden of cervical cancer in 177 countries for the five 
comparative scenarios (vaccine impact estimates for 
12-year-old girls are presented in appendix 1 pp 137, 138). 
Compared with the vaccination impact in the base scenario 
(S1), the demography update with the UNWPP 2019 
revision (S2) had the largest effect on estimates, resulting 
in a 33% increase in cases averted, a 50% increase 
in deaths averted, a 37% increase in YLD averted, a 
76% increase in YLL averted, and a 73% increase in DALYs 
averted per 1000 vaccinated girls for the bivalent or 
quadrivalent and nonavalent vaccines. Updating disability 
weights with values from the GBD 2017 study (S3) resulted 
in a 54% decrease in YLD and a 4% decrease in DALYs per 
1000 vaccinated girls for the bivalent or quadrivalent and 
nonavalent vaccines compared with S1, whereas it had no 
effect on cases, deaths, or YLL averted. Updating cervical 
cancer burden estimates with values from the GLOBOCAN 
2018 database (S4) resulted in a 7% decrease in cases and a 
6% decrease in YLD averted per 1000 vaccinated girls 
compared with S1, and resulted in a 2% increase in deaths, 
a 2% increase in YLL, and a 1% increase in DALYs averted 
per 1000 vaccinated girls compared with S1 for the bivalent 
or quadrivalent and nonavalent vaccines. The combined 
effect of updating the demography, disability weights, and 
cervical cancer burden estimates (S5) was an 18% decrease 
in YLD, a 26% increase in cases, a 51% increase in deaths, 
a 79% increase in YLL, and a 72% increase in DALYs 
averted per 1000 vaccinated girls for the bivalent or 
quadrivalent and nonavalent vaccines. Because the relative 
contribution of HPV 16/18 and HPV 16/18/31/33/45/52/58 
to cervical cancer cases remains the same irrespective of 
updates to demography, disability weights, and cervical 
cancer burden, the percentage changes in the health 
impact of HPV vaccination are the same for the bivalent or 
quadrivalent and nonavalent vaccines.
In the base scenario (S1) with the bivalent or 
quadrivalent vaccine, the numbers of 9-year-old girls 
that were needed to be vaccinated were 82 to prevent 
one case of cervical cancer, 132 to prevent one death, 
and seven to prevent one DALY; with the nonavalent 
vaccine, the numbers were 65 to prevent one case, 105 to 
prevent one death, and six to prevent one DALY (table 2). 
In the fully updated model (S5), for the bivalent or 
quadrivalent vaccine, the numbers of girls that needed 
to be vaccinated were 65 to prevent one case, 
87 to prevent one death, and four to prevent one DALY; 
for the nonavalent vaccine, the numbers needed were 
52 girls to prevent one case, 69 to prevent one death, 
and three to prevent one DALY.
The health impact of bivalent or quadrivalent and 
nonavalent HPV vaccination of 12-year-old girls at 
90% coverage during 2020–29 on the averted lifetime 
burden of cervical cancer in 177 countries for the 
five comparative scenarios is presented in appendix 1 
(p 139). The estimated numbers of 12-year-old girls 
needed to be vaccinated to prevent cervical cancer for the 
different scenarios are also presented (appendix 1 p 140). 
The estimated health benefits of vaccination of 12-year-
old girls are similar but slightly decreased compared with 
vaccination of 9-year-old girls.
The lifetime health impact of HPV vaccination of 
9-year-old girls during 2020–29 on disease burden 
averted in the six WHO regions is presented in figure 2 
and table 3 (regional vaccine impact estimates for 12-year-
old girls and for comparative scenarios are presented in 
appendix 1 [pp 141–67]). We estimate that the African 
region will gain the greatest health benefits from HPV 
vaccination, with 28 cases, 23 deaths, and 470 DALYs 
averted per 1000 vaccinated girls for the bivalent or 
quadrivalent vaccine, and 35 cases, 28 deaths, and 
581 DALYs averted per 1000 vaccinated girls for the 
nonavalent vaccine. The African region has a high per-
capita disease burden before vaccination, and therefore 
high numbers of cases, deaths, and DALYs would be 
averted after vaccination compared with other regions 
with lower per-capita disease burdens.
Figure 3 presents the national estimates for the lifetime 
health impact of HPV vaccination of 9-year old girls 
during 2020–29 on disease burden averted per 
1000 vaccinated girls in 177 countries, after the combined 
PRIME updates for demography, disability weights, 
and cervical cancer burden (see appendix 1 [pp 168, 169] 
for national estimates of vaccine impact for 12-year-
old girls). Based on country-specific lifetime estimates, 
we estimated that a mean of 17 cases (median 13 
[2·5th–97·5th percentile 3–51]), 12 deaths (9 [2–43]), 
9 YLD (7 [2–27]), 252 YLL (188 [40–849]), and 261 DALYs 
(195 [42–876]) would be averted per 1000 vaccinated girls 
in these 177 countries for the bivalent or quadrivalent 
vaccine. We estimated that a mean of 21 cases (16 [4–63]), 
15 deaths (10 [3–53]), 11 YLD (8 [2–33]), 314 YLL 
(237 [50–1049]), and 325 DALYs (244 [52–1082]) would be 
averted per 1000 vaccinated girls for the nonavalent 
vaccine. National estimates of HPV vaccination impact 
for the comparative scenarios are presented in the 
Bivalent or quadrivalent HPV vaccine* Nonavalent HPV vaccine†
1 case 1 death 1 YLD 1 YLL 1 DALY 1 case 1 death 1 YLD 1 YLL 1 DALY
S1 82 132 105 7·6 7·1 65 105 83 6 5·6
S2 61 88 77 4·3 4·1 49 70 61 3·4 3·3
S3 82 132 229 7·6 7·4 65 105 181 6 5·8
S4 88 129 112 7·5 7 70 102 89 5·9 5·6
S5 65 87 127 4·2 4·1 52 69 101 3·4 3·3
S1=Base scenario: WHO 2009 demography, GBD 2001 disability weights, GLOBOCAN 2012 cervical cancer burden. 
S2=Scenario 2: UNWPP 2019 demography, GBD 2001 disability weights, GLOBOCAN 2012 cervical cancer burden. 
S3=Scenario 3: WHO 2009 demography, GBD 2017 disability weights, GLOBOCAN 2012 cervical cancer burden. 
S4=Scenario 4: WHO 2009 demography, GBD 2001 disability weights, GLOBOCAN 2018 cervical cancer burden. 
S5=Scenario 5: UNWPP 2019 demography, GBD 2017 disability weights, GLOBOCAN 2018 cervical cancer burden. 
HPV=human papillomavirus. YLD=years lived with disability. YLL=years of life lost. DALY=disability-adjusted life-year. 
GBD=Global Burden of Disease study. GLOBOCAN=Global Cancer Incidence, Mortality and Prevalence. UNWPP=UN World 
Population Prospects. *Values are numbers of girls needed to be vaccinated to prevent cervical cancer caused by HPV 16/18. 
†Values are numbers of girls needed to be vaccinated to prevent cervical cancer caused by HPV 16/18/31/33/45/52/58.
Table 2: Numbers of 9-year-old girls that need to be vaccinated to prevent cervical cancer
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appendices (appendix 1 pp 170–211; appendix 2). Updated 
national estimates of HPV vaccination impact for 
bivalent or quadrivalent and nonavalent vaccination of 
9-year-old and 12-year-old girls are presented in 
appendix 1 (pp 212–39).
In comparison with the counterfactual scenario of no 
vaccination, routine vaccination of 9-year-old girls during 
2020–29 would have the greatest health benefits in 
eSwatini, Zambia, Malawi, Tanzania, Zimbabwe, and 
Burundi. 72, 63, 56, 54, and 53 cases of cervical cancer 
would be averted for the bivalent or quadrivalent vaccine 
and 88, 78, 69, 67, and 66 cases averted for the nonavalent 
vaccine per 1000 vaccinated girls in eSwatini, Zambia, 
Malawi, Tanzania, and Zimbabwe, respectively. 58, 47, 45, 
44, and 43 deaths would be averted for the bivalent or 
quadrivalent vaccine and 72, 59, 55, 54, and 54 deaths 
averted for the nonavalent vaccine per 1000 vaccinated 
girls in eSwatini, Zambia, Malawi, Burundi, and 
Zimbabwe, respectively. 1228, 966, 947, 903, and 
897 DALYs would be averted for the bivalent or 
quadrivalent vaccine and 1517, 1194, 1171, 1117, and 
1108 DALYs averted for the nonavalent vaccine per 
1000 vaccinated girls in Malawi, Burundi, eSwatini, 
Zambia, and Tanzania, respectively. The countries to 
potentially gain the largest HPV vaccination impact are 
the same for bivalent or quadrivalent and nonavalent 
vaccination of 9-year-old and 12-year-old girls.
Figure 2: Vaccination impact per 1000 vaccinated 9-year-old girls at the regional level
(A) Bivalent or quadrivalent vaccine. (B) Nonavalent vaccine. Values reflect lifetime health impact of HPV vaccination of 9-year-old girls during 2020–29 in the 
six WHO regions (estimates made after the combined PRIME updates for demography, disability weights, and cervical cancer burden). All values are numbers averted 
per 1000 vaccinated girls. DALY=disability-adjusted life-year. HPV=human papillomavirus. PRIME=Papillomavirus Rapid Interface for Modelling and Economics.
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Bivalent or quadrivalent HPV vaccine Nonavalent HPV vaccine
Cases Deaths YLDs YLLs DALYs Cases Deaths YLDs YLLs DALYs
African region 28 23 15 455 470 35 28 18 562 581
South-East Asia region 15 11 8 229 236 19 14 10 292 302
Region of the Americas 13 8 6 170 176 16 10 8 218 226
Western Pacific region 10 7 5 137 143 13 9 7 179 186
European region 9 5 4 117 121 11 6 5 141 147
Eastern Mediterranean 
region
6 4 3 93 96 7 6 4 116 120
Values reflect lifetime health impact of HPV vaccination of 9-year-old girls during 2020–29 in the six WHO regions 
(estimates made after the combined PRIME updates for demography, disability weights, and cervical cancer burden). 
All values are numbers averted per 1000 vaccinated girls. HPV=human papillomavirus. YLD=years lived with disability. 
YLL=years of life lost. DALY=disability-adjusted life-year. PRIME=Papillomavirus Rapid Interface for Modelling and 
Economics.
Table 3: Vaccination impact per 1000 vaccinated 9-year-old girls at the regional level
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The countries that will experience the largest health 
benefits through HPV vaccination are all in the WHO 
African region. Within the other regions, the countries 
that will experience the greatest number of DALYs 
averted through HPV vaccination are the Maldives, 
Indonesia, and Nepal in the South-East Asia region; 
Bolivia, Jamaica, and Belize in the region of the Americas; 
Fiji, the Solomon Islands, and Papua New Guinea in 
the Western Pacific region; Kyrgyzstan, Romania, and 
Lithuania in the European region; and Morocco, Somalia, 
and Djibouti in the Eastern Mediterranean region.
In comparison with previous estimates, the updated 
estimates resulted in increases in the numbers of cervical 
cancer cases averted per 1000 vaccinated girls in most 
countries, with the greatest increases in eSwatini, 
Namibia, Lesotho, Burkina Faso, and Iceland. The 
greatest increases in the numbers of deaths averted per 
1000 vaccinated girls were in Malta, eSwatini, Namibia, 
Lebanon, and Samoa, and in DALYs averted per 
1000 vaccinated girls were in Iceland, Malta, Bahrain, 
Maldives, and eSwatini. These increases in cases, deaths, 
and DALYs averted are primarily due to the demography 
update of UNWPP 2019, which includes increasing life 
expectancy and population aging among women in these 
countries, and a relative increase in cervical cancer 
burden estimates from the GLOBOCAN 2018 database.
The updated HPV vaccination impact estimates for 
cases, deaths, and DALYs averted per 1000 vaccinated 
girls are lower than the previous estimates for 49, 18, 
and eight countries, respectively. These decreases are 
primarily due to lower estimates of cervical cancer 
burden for these countries in the GLOBOCAN 2018 
Figure 3: Impact of HPV vaccination of 9-year-old girls at the national level
(A) Bivalent or quadrivalent vaccine. (B) Nonavalent vaccine. DALY=disability-adjusted life-year. HPV=human papillomavirus. Grey shading indicates no data were available.
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database compared with the GLOBOCAN 2012 database. 
The changes in vaccination impact between the different 
comparative scenarios (S2–5) compared with the base 
scenario (S1) for vaccination of 9-year-old and 12-year-old 
girls are provided in appendix 1 (pp 240–320).
Discussion
We updated PRIME with demography from the UNWPP 
2019 revision, disability weights from the GBD 2017 
study, and cervical cancer burden from the GLOBOCAN 
2018 database. We assessed the effects of these updates 
on the health impact estimates generated by the model 
for bivalent or quadrivalent and nonavalent vaccination 
of 9-year-old and 12-year-old girls at 90% coverage during 
2020–29 at the global, regional, and national levels for 
177 countries. After these updates, we found that HPV 
vaccination provides larger health benefits than 
previously estimated, because the number of girls 
needed to be vaccinated to prevent a single case, death, 
or DALY are lower than previous forecasts.11 Vaccination 
is also more cost-effective than previously estimated, 
because the number of cases, deaths, and DALYs averted 
per vaccinated girl is higher than our earlier estimates. 
Furthermore, because of a higher burden of cervical 
cancer before vaccination in the WHO African region 
compared with other regions, HPV vaccination will 
provide the greatest relative health benefits in this 
region and the countries within this region should be 
prioritised for HPV vaccine introduction and scale-up. 
Based on WHO-initiated guidance on priority setting 
in health care,24 the African region has the greatest 
potential to benefit from HPV vaccination, followed by 
the South-East Asia region, the region of the Americas, 
Western Pacific region, European region, and Eastern 
Mediterranean region.
We found that the demography update from the WHO 
2009 life tables to the UNWPP 2019 revision was the 
major driver for change in the health impact estimates of 
PRIME, in comparison with the updates to disability 
weights or cervical cancer burden estimates. Because 
UNWPP mortality estimates are declining over time and 
incorporate population aging (unlike static WHO life 
tables), using UNWPP 2019 estimates led to an increasing 
life expectancy among women and a subsequent increase 
in lifetime risk of cervical cancer incidence and mortality 
without vaccination. Therefore, HPV vaccination provides 
greater benefits in preventing new cases and deaths than 
previously estimated.
HPV vaccination could have an even greater impact 
and be more cost-effective than predicted in this study, 
because some assumptions in PRIME are conservative 
and likely to underestimate the impact of vaccination. 
These conservative assumptions and study limitations 
are that herd effects are not considered; vaccination is 
considered to have no effect on women after sexual 
debut; cervical cancer incidence is assumed to remain 
constant in the absence of preventive interventions; and 
cross-protection against non-vaccine HPV genotypes is 
excluded. Other limitations are exclusion of transmission 
dynamics of HPV infection and natural history of 
precancer lesions; exclusion of changes in coverage and 
effectiveness of non-vaccine interventions (ie, screening 
and treatment of precancer lesions); and exclusion of 
changes in coverage and effectiveness of treatment and 
care of cervical cancer cases. The combined impact of 
vaccine and non-vaccine interventions are significant 
strategic considerations, and the working draft of the 
WHO 90–70–90 cervical cancer elimination strategy has 
set targets of achieving 90% coverage of HPV vaccination; 
70% coverage for screening and 90% treatment of 
precancer lesions; and 90% treatment and care of cervical 
cancer cases.10 PRIME complements models that include 
additional features to analyse the potential impact of 
comprehensive cervical cancer prevention and control 
programmes and supports strategic decision making.
The structural uncertainty and variability between 
HPV vaccine impact models warrants a comparison of 
the models to identify key drivers of the conclusions on 
the effectiveness and cost-effectiveness of vaccination.25,26 
Evidence synthesis from different models will improve 
the fidelity of the decision-making process in formulating 
the optimal strategy for cervical cancer elimination 
within a century.27,28 Although we infer that demographic 
assump tions are key drivers of HPV vaccine impact 
predictions in this study, demography is a critical input 
to modelling the health and economic impact of 
vaccination in general.
Sexual debut data by age for 67 countries are included 
in this study and future directions include estimation for 
other countries. Although we have not explored the 
impact of changes in sexual behaviour, countries that 
are transitioning from traditional age-specific sexual 
behaviour to gender-similar age-specific sexual behaviour, 
with increases in the average number of partners and the 
number of partners women have before marriage, are 
likely to result in increased prevalence of HPV infection 
and incidence of cervical cancer.29
PRIME updates for demography, disability weights, 
and cervical cancer burden improve the fidelity of the 
projections of HPV vaccination impact at the global, 
regional, and national levels, and provide essential 
information for decision making in the era of achieving 
cervical cancer elimination. Given that cervical cancer 
elimination is likely to take many decades, HPV vaccine 
impact models must be continually updated to reflect 
new knowledge about parameter estimates and disease 
burden.11,30,31 The updated PRIME estimates for HPV 
vaccination impact suggest greater health benefits and 
therefore increased cost-effectiveness of vaccination in 
comparison with previous estimates. Investments to 
increase HPV vaccination coverage and equity need to be 
continued, and countries in the WHO African region 
should be prioritised for HPV vaccine introduction and 
scale-up.
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